Xlife Sciences AG
SIX:XLS

Watchlist Manager
Xlife Sciences AG Logo
Xlife Sciences AG
SIX:XLS
Watchlist
Price: 29.1 CHF 0.69% Market Closed
Market Cap: 167.1m CHF
Have any thoughts about
Xlife Sciences AG?
Write Note

Xlife Sciences AG
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xlife Sciences AG
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Xlife Sciences AG
SIX:XLS
Cash & Cash Equivalents
CHf218.7k
CAGR 3-Years
-64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Cash & Cash Equivalents
CHf62.7m
CAGR 3-Years
46%
CAGR 5-Years
39%
CAGR 10-Years
10%
Siegfried Holding AG
SIX:SFZN
Cash & Cash Equivalents
CHf64.5m
CAGR 3-Years
3%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Cash & Cash Equivalents
CHf1.2B
CAGR 3-Years
34%
CAGR 5-Years
24%
CAGR 10-Years
16%
Tecan Group AG
SIX:TECN
Cash & Cash Equivalents
CHf108.3m
CAGR 3-Years
-20%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Cash & Cash Equivalents
CHf85.1m
CAGR 3-Years
10%
CAGR 5-Years
191%
CAGR 10-Years
N/A
No Stocks Found

Xlife Sciences AG
Glance View

Market Cap
166m CHF
Industry
Life Sciences Tools & Services

Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company is headquartered in Zurich, Zuerich and currently employs 19 full-time employees. The company went IPO on 2019-09-30. The firm focuses on investing in technologies in the life science industry. The company supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The firm offers its investors direct access to the further development of technologies at a very early stage. The firm cooperates with industrial partners and universities.

XLS Intrinsic Value
1.37 CHF
Overvaluation 95%
Intrinsic Value
Price

See Also

What is Xlife Sciences AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
218.7k CHF

Based on the financial report for Dec 31, 2023, Xlife Sciences AG's Cash & Cash Equivalents amounts to 218.7k CHF.

What is Xlife Sciences AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
-64%

Over the last year, the Cash & Cash Equivalents growth was -1%. The average annual Cash & Cash Equivalents growth rates for Xlife Sciences AG have been -64% over the past three years .

Back to Top